ArticlePloS one2024

Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.

Shinpei Yamaba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.